pegasu readout phase catalyst
preview thought ahead pegasu apelli phase pnh studi
expect read earli januari investor calibr portfolio
provid scenario analysi pegasu coupl upside/
downsid assess see exhibit view skew upsid also
add thought ga franchis expect becom meaning
element invest thesi move independ pegasu
juli initi pnh might ice point anticip
focu ga thesi follow execut pnh read immin
ahead pegasu reiter outperform rate stay bullish
base upside/downsid assess believ risk-reward slant
posit go readout estim suggest move
follow posit data readout scenario combin likelihood
chanc neg readout safeti and/or efficaci lower share
share note incorpor consider agreement sfj
despit investor focu versu improv hb believ
discuss lose sight randomized-withdraw natur
studi place head-to-head soliri bar
conveni proxi studi power demonstr
statist superior focus varianc outcom assist
overenrol
pegasu read favor could observ file
conserv estim order includ full safeti
review timelin could also emb regulatori clariti abil
file pegasu data independ pre-nda file meet
agenc
pegasu read unfavor note anticip move
current share price appreci underli cad
opportun pnh unsuccess could remain clinic viabl
perhap commerci even bar safeti event view cad
opportun rel overshadow pnh commerci market
ga could move forefront consid phase readout
derbi oak expect base recent investor call
key opinion leader treat retin diseas remain bullish larg
widen unmet need geograph atrophi first-in-class best-
in-class potenti address condit
year price histori
develop pegcetacoplan
current phase develop
pnh geograph atrophi ga
found apelli base
analyst certif import disclosur see disclosur
inhibit potenti address
two potenti blockbust indic signific unmet
need ga pnh believ potenti
address meaning proport pnh market
alreadi commerci develop alexion
therapeut soliri eculizumab ultomiri
ravulizumab ga howev treatment exist
sever late-stag diseas believ opportun set
eye could rival potenti exceed
regeneron flagship eylea aflibercept franchis
constrast also face brand ranibizumab/brolucizumab
demonstr hemoglobin improv least
improv secondari compar eculizumab phase
enrol phase derbi oak complet end
januari phase pegasu readout pnh
complet enrol phase ga studi
phase derbi oak readout ga
demonstr hemoglobin improv improv
transfus independ compar eculizumab phase
enrol phase derbi oak complet end
demonstr clinic signific benefit ga pnh
cad
employ composit valuat methodolog biotechnolog compani util revenu multipl discount cash flow analysi
respect development-stag compani place greater weight revenu multipl compar dcf analysi due
latter sensit long-run assumpt price target blend revenu multipl calcul dcf
valuat
appli revenu multipl pnh multipl ga lie rang industri averag
probabl success drug approv pnh ga
appli discount rate line smid-cap biotech
clinic efficaci fail meet clinic efficaci endpoint program pnh ga cad
clinic safeti safeti signal emerg clinic studi
manufactur risk manufactur issu could hinder regulatori approv limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti
negoti payor could limit market opportun
financ apelli may requir addit fund conduct addit studi commerci
statement oper
thousand except per share
good sold
research develop
loss extinguish debt
loss remeasur develop deriv liabil
loss remeasur fair valu warrant deriv
comprehens loss net tax
net profit loss per common share basic dilut
weight average common share basic dilut
thousand
cash equival
refund research develop credit
properti equip net
liabil stockhold equiti
current portion long-term debt
current portion right use liabil
addit paid capit
accumul comprehens incom
total liabil stockhold equiti
statement cashflow
thousand
loss earli extinguish debt
loss remeasur fair valu warrant
amort right-of-us asset
accret discount
refund research develop credit
net cash use oper activ
purchas properti equip
net cash use invest activ
issuanc seri convert prefer stock net issuanc
repay promissori note
payment cap call transact associ cost
proce issuanc common stock net issuanc cost
proce develop deriv liabil
proce exercis stock option warrant
proce issuanc term loan net issuanc cost
proce issuanc promissori note payabl
affili stockhold
proce issuanc common stock warrant
repay term loan
net cash provid financ activ
effect exchang rate chang cash cash equival
net increas decreas cash equival
cash equival begin period
cash equival end period
million
patient pnh
pnh patient treat
patient pnh
pnh patient treat
million
patient ga
ga patient treat
adult year age
patient ga
ga patient treat
popul
assumpt multipl tab
nwc revenu
npv
million except per share
pnh program multipl analysi million
current probabl success po pnh
ga program multipl analysi million
round
chang
likelihood event
probabl success po
chang po
incr/decr pt
gains-to-loss current share level
pt new scenario
impli market cap million
chang
weak efficaci
assum increas peak penetr versu current
weak could exceed fundament valuat due sentiment time next clinic catalyst
